ROAR trial: which treatment is effective after progression? - Authors' reply.
Saved in:
| Title: | ROAR trial: which treatment is effective after progression? - Authors' reply. |
|---|---|
| Authors: | Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: patrick_wen@dfci.harvard.edu., Burgess P; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals, Basel, Switzerland., Ilankumaran P; Global Drug Development, Oncology Development Unit, Novartis Pharma, East Hanover, NJ, USA., Subbiah V; Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2022 Mar; Vol. 23 (3), pp. e94. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-5488 |
|---|---|
| DOI: | 10.1016/S1470-2045(22)00076-6 |
